There is increasing evidence that breast and other cancers originate from and are maintained by a small fraction of stem/progenitor cells with self-renewal properties. Whether such cancer stem/progenitor cells originate from normal stem cells based on initiation of a de novo stem cell program, by reprogramming of a more differentiated cell type by oncogenic insults, or both remains unresolved. A major hurdle in addressing these issues is lack of immortal human stem/progenitor cells that can be deliberately manipulated in vitro. We present evidence that normal and human telomerase reverse transcriptase (hTERT)-immortalized human mammary epithelial cells (hMECs) isolated and maintained in Dana-Farber Cancer Institute 1 (DFCI-1) medium retain a fraction with progenitor cell properties. These cells coexpress basal (K5, K14, and vimentin), luminal (E-cadherin, K8, K18, or K19), and stem/progenitor (CD49f, CD29, CD44, and p63) cell markers. Clonal derivatives of progenitors coexpressing these markers fall into two distinct types-a K5 + /K19
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immortalization | in vitro stem cell model | mammary epithelial cells | selfrenewal | stem cell B reast cancer is a genetically and clinically heterogeneous disease (1). It is unclear whether different target cells contribute to this heterogeneity and which cell types are most susceptible to oncogenesis. Recent molecular profiling has identified five major subtypes of breast cancers: a basal epithelium-like group, an ErbB2-overexpressing group, a normal breast epithelium-like group, and two luminal epithelial cell types with significantly different outcomes for patients belonging to various groups (2) . The correspondence of some breast cancer subtypes with cell types present in the normal mammary gland (such as basal and luminal) strongly supports the idea that breast tumor subtypes may represent malignancies of biologically distinct cell subtypes. Alternatively, different types of breast cancers may arise from a common precursor, based on distinct pathways of oncogene-driven reprogramming. Heterogeneity in cancers is ascribed to clonal evolution as a result of inherent genomic instability of tumor cells and tumor-host interactions (3). The stem cell hypothesis suggests an alternate explanation with tumor heterogeneity reflecting the relative fraction of cancer stem/progenitor cells and differences in their abilities to produce progeny at various stages of differentiation. Although current literature supports each of these ideas, definitive studies to favor one or the other model, or both hypotheses, are lacking.
Recent progress in cancer biology has been substantially facilitated by in vitro models. Strategies to culture and efficiently immortalize human mammary epithelial cells (hMECs) led to landmark findings that expression of a limited set of oncogenes and/or loss of tumor suppressor genes together with imparting immortal behavior was sufficient to induce malignant transformation of normal hMECs (4) . Use of culture models has also suggested the possibility for reprogramming hMECs as demonstrated by the attainment of stem cell-like epithelial mesenchymal transition (EMT) upon manipulation of gene expression (5) . Unfortunately, the fundamentally important questions related to origin of cancers have been difficult to address due to lack of tractable cellular models of mammary stem/progenitor cells that can be continuously cultured in vitro and would be suitable for detailed cellular and biochemical analyses and to interrogate their potential for oncogenic transformation.
Here, we have isolated and characterized human telomerase reverse transcriptase (hTERT)-immortalized clonal cell populations that are enriched for markers of normal mammary stem/ progenitors cells. We show that the immortalized stem/progenitor cells maintain their self-renewal ability but can also be induced to differentiate. The presence of related cell populations in the normal mammary gland together with gene expression analyses further support the idea that immortalized cell lines characterized here represent genuine human mammary stem/progenitor cells. These unique cellular tools should prove invaluable in future studies to answer important questions related to breast cancer, such as the origin of breast cancer stem/progenitor cells and mechanisms of heterogeneity in breast cancers.
Results
Primary and hTERT-Immortalized hMECs Isolated and Cultured in DFCI-1 Medium Express Stem/Progenitor Cell Markers. We have previously developed a medium designated as Dana-Farber Cancer Institute 1 (DFCI-1) to isolate and propagate hMECs from mammoplasty and mastectomy tissues (6, 7) . We have shown that hMECs cultured in DFCI-1 medium proliferate for 10-20 population doublings, followed by a selection (crisis) and emergence of a postselection cell population with a typical life span of about 60 population doublings before senescence (6, (8) (9) (10) . Our earlier 2-D gel analyses showed that the hMECs coexpress both basal (K5 and K14) and luminal (K8 and K18) types of cytokeratins, suggestive of their being progenitor/stem cells (11, 12) . Given their limited life span, we used retroviral infection to introduce a cellular gene hTERT into preselection hMECs at passage 2 to isolate immortalized hMECs and assessed the expression of hMEC lineagerelated and stem/progenitor cell markers using Western blotting. These analyses demonstrated that two distinct primary hMECs and their TERT-immortalized derivatives propagated in DFCI-1 medium express both basal (K5, K14, p63, and vimentin) and luminal (K8, K18, and E-cadherin) cell markers; one cell strain (70N) also expressed K19, a known luminal cell marker (Fig.1A) . In addition both hMECs and their TERT-immortalized derivatives expressed CD29, a known stem cell marker (13), but did not express detectable levels of differentiated luminal cell marker MUC1 (14, 15) or differentiated myoepithelial cell marker α-smooth muscle actin (α-SMA) (14, (16) (17) (18) (Fig.1A) . Consistent with other findings, despite expression of several luminal cell markers, the primary and TERT-immortalized hMECs lacked the expression of estrogen receptor α (ER-α) (19, 20) .
Next, we carried out immumofluorescence staining to assess whether different lineage markers were expressed on same cells or on non-overlapping cells. Notably, every cell in primary and immortal culture expressed K5, K14, vimentin, and E-cadherin, as well as a known stem cell marker CD49f (21) (Fig. 1B) , indicating that stem/progenitor characteristics were maintained through immortalization.
Isolation of Distinct hMEC Stem/Progenitors Through Cloning.
Whereas most luminal breast cancers are K19 positive (14), we found K19 expression on primary as well as TERT-immortalized hMECs to be variable. K19 was essentially undetectable in 76N and 76N.TERT lines, whereas 70N cells showed easily detectable K19 (Fig. 1A) . Further immunostaining analysis showed heterogeneous K19 expression (Fig. S1) (Fig.3A) and subsequently a proportion of cells near the periphery adopted a spindle-shaped morphology surrounding the tight epithelial cell colony in the center (Fig. 3A) . Notably, while the cells in the center expressed the basal, luminal, and stem cell markers like the cells cultured in DFCI-1 medium (Figs. 1B and 3B) , the spindle-shaped cells forming the peripheral halo were K5 negative (Fig. 3C) (Figs. S2 and S3 ). The antibodies used to establish the identity of peripheral cells as myoepithelial were indeed specific as demonstrated by their specific staining of myoepithelial components in healthy breast tissue (Fig. S4) . Notably, differential trypsinization allowed us to isolate the central compact colonies separately from the cells forming the peripheral halo followed by replating to assess their ability to continue to proliferate: the central compact part of colonies could be repeatedly plated to regenerate similar colonies as well as to generate differentiated myoepithelial halos in MEGM medium. In contrast, the differentiated myoepithelial cells in the peripheral halo quickly lost the ability to attach and failed to proliferate. We have continuously maintained these cell cultures for more than 1 y and observed that the tight cells continued to proliferate and exhibit self-renewal and differentiation abilities. The retention of these abilities strongly support the conclusion that the immortalized K5 + cell types in our defined medium DFCI-2 (6, 7) we did not observe myoepithelial differentiation but consistently observed appearance of MUC1-positive and vimentin-negative cells (Fig.  4B) ; these results suggest that DFCI-2 medium may favor luminal differentiation or selectively inhibit myoepithelial differentiation. Notably, FACS-sorted MUC1-positive cells from both cell types failed to attach or proliferate and therefore cannot be used for + cells express a number of genes previously associated with stem/progenitor cell populations whose expression was also modulated upon myoepithelial cell differentiation including components of Notch, Wnt, hedgehog pathways, and other genes such as LIF and KLF5 (Table 1) . Notably, aldehyde dehydrogenase 1A3 enzyme (ALDH1A3), a marker used to isolate normal and tumor mammary stem cells (23, 24) , was ≈400-to 500-fold higher in K5 + /K19 − and K5 + /K19 + cell types, relative to differentiated myoepithelial cells (Table 1) . Indeed, we confirmed changes in ALDH mRNA levels between K5 + /K19 − cell type and their differentiated myoepithelial progeny by real-time PCR and ALDEFLUOR FACS analyses (Fig. S5) + cell types were isolated on the basis of differences in only K19 expression, microarray analyses demonstrated a substantial number of gene expression differences between these two cell types (Table S1 ) consistent with the possibility that these cells may reflect distinct progenitor stages.
Discussion
It is now generally accepted that breast cancers harbor cells with stem cell markers suggesting their role in the initiation and/or maintenance of tumors (25) (26) (27) (28) . It is however unclear whether such cancer initiating or cancer stem cells originate from normal stem cells or represent reprogramming of tumor cells to attain stem celllike phenotypes. In fact, deliberate oncogenic transformation of a human mammary stem cell has not been possible. A critical barrier to address these basic issues is a lack of well-defined hMEC stem/progenitor cells that can be subjected to oncogenesis studies. Here, we report the characterization of hTERT-immortalized hMECs with stem/progenitor properties that provide tools for such studies. Definitive demonstration of mammary stem cells in the mouse predicts that similar cells exist in human mammary gland. This idea is supported by immunohistochemical studies of human mammary gland as well as demonstration of stem cell-like traits, including stem cell marker expression, limited in vitro selfrenewal in mammospheres, induced lineage differentiation, and an ability to form mammary tissue when xeno-transplanted in mouse mammary fat pad with freshly isolated hMECs. However, normal hMECs with such stem cell characteristics have not been propagated in long-term culture. Thus, our indefinite propagation of two different types of immortal hMECs with stem/progenitor characteristics represents a significant step forward in breast cancer cell biology.
The concurrent presence of markers associated with basal, luminal, and stem/progenitor cell compartments in both primary hMEC cultures and in hTERT-immortalized hMECs suggested that our culture conditions promoted the maintenance of stem/ progenitor cell properties potentially through their self-renewal. Analyses of clonally derived cell lines not only established that this was the case but also led to the identification of distinct stem/ progenitor cell types. These cells demonstrate an ability to continuously proliferate and maintain composite marker profiles of basal, luminal, and stem cells. When these cells are cultured in media known to promote lineage differentiation of freshly isolated hMECs, a subset of epithelium-like cells perpetuate the marker profiles of parental clones and can be propagated, suggesting their capability to self-renewal. Notably, the cells that reproducibly form a sheath of elongated spindle-shaped cells around the central epithelial colony attain myoepithelial markers. Furthermore, a small number of cells within the central mass of colonies in differentiation cultures become MUC1 positive/ vimentin negative, consistent with differentiation along the luminal pathway. Both K5 + /K19 − and K5 + /K19 + cell types do not represent a peculiarity of in vitro cell culture but such cells exist in vivo in normal human mammary gland. The immortalized clonal hMECs we have obtained exhibit markers of stem cells similar to those defined by others (13, 19, 21, 23, 29) . It is remarkable, however, that immortal hMECs maintain their stem/progenitor characteristics in 2-D culture apparently without need for any additional cell type.
It is notable that we have been able to identify two distinct types of hMEC stem/progenitors, initially based on K19 expression but with additional differences as suggested by gene expression analyses (Table S1) , and these cells are present in human mammary tissues (Fig. 2D) . In a previous study, cell sorting based on surface antigen markers (MUC1 and ESA) was shown to identify MUC + cell types differentiated along a luminal pathway could not be propagated further, suggesting near-terminal differentiation. In contrast, some myoepithelial cells were able to continuously proliferate when transferred from MEGM to DFCI-1 medium; however, others were unable to proliferate, suggesting that both cell types are able to differentiate into myoepithelial progenitor as well as terminally differentiated myoepithelial cells. These results suggest that in addition to differentiation programs assessed using available markers, these cells are able to undergo irreversible cell cycle arrest associated with differentiation despite ectopic hTERT expression. Thus, the cells isolated here may be useful to study events associated with terminal differentiation of hMECs into myoepithelial and luminal cells.
A number of key gene regulatory pathways including components of the Wnt, Notch, and hedgehog pathways, and other stem cell control genes are involved in the maintenance of embryonic stem cell self-renewal and are also modulated upon adult stem cell self-renewal and differentiation (15, (30) (31) (32) (33) (34) (35) (36) (37) . Our gene expression profiling demonstrates that these pathways are expressed in stem/ progenitor hMECs and notably are prominently modulated upon differentiation along the myoepithelial lineage (Table 1 ). Due to a relatively low frequency of cells differentiating along the luminal pathway and an inability of these differentiated cells to be propagated has thus far prevented us from comparing specific alterations in gene expression associated with luminal pathway of differentiation. Further studies to define conditions that yield high proportion of luminal lineage differentiated cells would therefore be instructive. The propagation of distinct immortal clonal hMEC lines that appear to represent relatively early stem/ progenitor cells, together with our ability to generate myoepithelial and luminal progeny upon differentiation of both cell types suggest that our culture conditions allow stable maintenance of hMECs at multiple stem/progenitor stages, something that will be of significance in deliberate efforts to establish immortal mammary progenitors "frozen" at different stages along the differentiation hierarchy.
The present findings provide proof of principle that it is possible to isolate hMECs that represent stem/progenitor stages as immortal lines that can be perpetuated and induced into differ- entiation. Use of hTERT a cellular gene rather than viral oncogenes provides a more physiological model for understanding stem cell biology. Future efforts using this approach may help identify additional stem/progenitor stages in hMECs. More importantly, these immortal stem/progenitors will be suitable for deliberate oncogenesis studies to test whether indeed their transformation can lead to tumors and if such transformed cells will resemble tumor stem cells. Although stem/progenitor analyses were not carried out, earlier studies by Weinberg's group have shown that primary hMECs can be rendered fully tumorigenic upon introduction of a defined number of oncogenes and loss of tumor suppressors (4). We and others have previously shown that hMECs are highly susceptible to immortalization upon ectopic expression of cellular genes (10, (38) (39) (40) (41) , viral genes (7, 38) , carcinogens (42) , and radiation (43) . We also noted that primary hMECs at early or late passages exhibited differential susceptibility to immortalization by human papilloma virus (HPV) E6 and E7 or their combinations (7, 8, 12) . It is reasonable to suggest that the propensity of hMECs to be transformed by ectopic oncogene expression and/or down-regulation of tumor suppressors may indeed be related to the susceptibility of stem/progenitor cells to oncogenesis. The cell lines established here should allow direct examination of these critical issues.
Materials and Methods
Cell Strains and Cell Culture. hMEC strains 76N and 70N were grown in DFCI-1 medium, as described earlier (6) (7) (8) . Human telomerase (hTERT)-immortalized cells were grown in DFCI-1 medium supplemented with 100 μg/mL G418 (Sigma). DFCI-2 and mammary epithelial growth medium (MEGM) have been described previously (6, 7) . subcloned three times to ensure that each clone was derived from a single cell.
Self-Renewal and Differentiation. Cells were grown in serum-free MEGM medium (Lonza) supplemented with B27 (10 mL/500 mL medium, Invitrogen), 20 ng/mL EGF (Invitrogen), 20 ng/mL bFGF (BD Biosciences), and 4 μg/mL heparin (Sigma) without bovine pituitary extract (16) . Both types of cells were also cultured in DFCI-2 medium (6, 7) to obtain luminal differentiation. The details of the materials and methods for antibodies used in the study, retroviral infection and immortalization of hMECs, Western blotting, immunofluorescence of cells and tissues, Affymetrix microarray analyses, realtime PCR, and FACS analysis of ALDH expression can be found in SI Materials and Methods.
